Theravance Biopharma, Inc. (TBPH)
↓ Download CSV- Sector Manufacturing
- Incorporated CA
- Fiscal year ends Dec 31
In fiscal 2025, Theravance Biopharma, Inc. reported revenue of $107.46M, up 66.9% from the prior year. The company was profitable, with a net margin of 98.5%.
Key ratios (FY2025)
-3.4%
Operating margin
98.5%
Net margin
35.7%
Return on equity
+66.9%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $107.46M | $64.38M | $57.42M | $51.35M | $55.31M | $71.86M | $73.41M | $60.37M | $15.39M | $48.65M |
| Cost of Revenue | — | — | — | — | — | — | — | — | $6.03M | $2.89M |
| Operating Income | -$3.60M | -$46.95M | -$56.03M | -$91.96M | -$257.78M | -$297.63M | -$251.91M | -$238.75M | -$260.12M | -$180.47M |
| Net Income | $105.89M | -$56.42M | -$55.19M | $872.13M | -$199.43M | -$278.02M | -$236.46M | -$215.52M | -$285.40M | -$190.67M |
| EPS (Diluted) | $2.06 | $-1.15 | $-1.00 | $11.85 | $-2.87 | $-4.46 | $-4.25 | — | — | — |
| Total Assets | $485.57M | $354.16M | $382.00M | $607.40M | $374.82M | $469.06M | $408.83M | $560.24M | $441.40M | $639.25M |
| Shareholders' Equity | $296.72M | $175.54M | $213.00M | $441.80M | -$338.57M | -$303.75M | -$223.84M | -$51.59M | $115.18M | $350.23M |
| Cash & Equivalents | $167.81M | $37.80M | $39.55M | $298.17M | $89.96M | $81.47M | $58.06M | $378.02M | $88.98M | $344.71M |
| Operating Cash Flow | $238.54M | -$11.54M | -$27.00M | -$186.99M | -$207.86M | -$250.40M | -$238.20M | -$112.87M | -$201.05M | -$98.99M |
| Capital Expenditures | $42.0K | $332.0K | $2.49M | $572.0K | $3.41M | $6.62M | $3.18M | $7.24M | $2.41M | $2.13M |
| Shares Outstanding | 51.07M | 49.47M | 48.09M | 65.23M | 74.44M | 64.33M | 57.02M | 55.68M | 54.38M | 52.83M |